

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	G protein-coupled receptor 126 (GPR126); VEGF receptor 2 (KDR/Flk-1; VEGFR-2)	<i>In vitro</i> , mouse and zebrafish studies suggest inhibiting GPR126 could help treat cancer and other disorders associated with increased angiogenesis. In a mouse model of oxygen-induced retinopathy, shRNA against <i>Gpr126</i> decreased pathogenic vessel formation compared with control shRNA. In zebrafish, morpholinos targeting <i>gpr126</i> inhibited vessel outgrowth, whereas a control morpholino did not. In human endothelial cells, shRNA against GPR126 led to lower expression of transcription factors that promote VEGFR-2 expression than a control vector. Next steps could include developing a small molecule GPR126 inhibitor. <i>SciBX</i> 7(40); doi:10.1038/scibx.2014.1173 Published online Oct. 16, 2014	Patent and licensing status unavailable	Cui, H. <i>et al.</i> <i>J. Biol. Chem.</i> ; published online Sept. 12, 2014; doi:10.1074/jbc.M114.571000 Contact: Mingyao Liu, East China Normal University, Shanghai, China e-mail: mlliu@bio.ecnu.edu.cn Contact: Dali Li, same affiliation as above e-mail: dlli@bio.ecnu.edu.cn Contact: Yanlin Ma, Hainan Reproductive Medical Center, Affiliated Hospital of Hainan Medical University, Haikou, China e-mail: may1990@foxmail.com